Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

24/07/2019 Port de Barcelona will have a rolling highway terminal 04/07/2019 New software to promote urban district heating and cooling networks 07/06/2019 Biodiversity in danger: Barcelona Synchrotron Park’s actions 28/05/2019 The UAB ranks first according to the CYD Foundation 23/05/2019 Alba: open day, workshop and last results 25/04/2019 The UAB Scientific and Technical Services: an opportunity for BSP’s companies
3 4 5 6 7 8 9 10 11 12 13